No. 1 Hair Loss Treatment

Novel Treatments

15
September
2009

Aderans's Hair Regeneration Project Entered Phase II Clinical Testing

Aderans, the main competitor of the financially-struggling market leader in the area of hair regeneration, Intercytex, has recently launched a Phase II clinical study on cell-based hair regeneration for men and women. Hair regeneration, also known as hair multiplication, hair cloning or follicular neogenesis...

Read more

05
May
2009

Intercytex Facing Serious Financial Difficulties

Skin regeneration specialist Intercytex put itself up for sale following the failure of a Phase III study of its leading project involving Cyzact, a therapy for healing chronic wounds caused by venous leg ulcers. This failure, combined with poor economic results in 2008, leaves the company struggling to secure financing for its existing projects.

Read more

27
August
2008

Telomerase a New Fountain of Youth?

Telomerase is an enzyme that adds specific DNA sequence repeats to the end of DNA strands in the telomere regions. Telomerase consists of two molecules each - telomerase reverse transcriptase (TERT), telomerase RNA (TERC) and dyskerin. By using TERC, TERT can add a specific six-nucleotide repeating sequence to the strand of chromosomes. These repeats are called telomeres.

Read more

01
May
2008

Intercytex Reports Further Progress

In March 2008, Intercytex reported the latest results on its progress in the phase II clinical study of ICX-TRC. ICX-TRC is a suspension of a patient’s own dermal papilla cells that is injected into the patient scalp to stimulate new hair growth. Intercytex is a frontrunner in the development of hair multiplication. The latest results are consistent with the earlier data...

Read more

19
February
2008

Intercytex Making Progress

Hair multiplication may be the next big step in surgical hair restoration. Several medical teams on three continents are currently researching hair multiplication. The UK-based firm Intercytex appears to be the frontrunner. Their latest report on the Phase II clinical study of ICX-TRC...

Read more

14
February
2008

Generating New Hair Follicles

Follica, a US-based medical device company, is developing a novel approach that consists in generating completely new hair follicles in wounds of hair-free skin. This technique was licensed from the University of Pennsylvania. Researchers studying skin healing processes at the university noticed that new hair follicles formed in the middle of some wounds...

Read more

18
January
2008

NEOSH101 Phase IIb Results Are Pending

NEOSH101 is a proteasome inhibitor (a potential osteoporosis cure), being presently developed into a hair loss remedy by the dermatology-focused specialty pharmaceutical company called Neosil. It is currently undergoing Phase IIb clinical trials for its targeted FDA approval conducted in Germany...

Read more